For research use only
| Cat No. | ABL-TC0464 |
| Product Type | Human Germ Cell Cancer Cell Lines |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Testis |
| Product Code | NEC-8 |
NEC8 cells grow adherently and express cancer stem cell genes, showing strong tumorigenic potential and trophoblastic differentiation abilities.
The NEC8 cell line is an established human embryonal carcinoma model derived from a primary testicular germ cell tumor of a 24-year-old East Asian male. NEC8 cells grow adherently with epithelial-like morphology and form dense solid cell aggregates. They show characteristic features including high expression of chemoresistance-associated globo-series glycosphingolipids (Gb3, Gb4), stem cell markers (OCT4, NANOG, GADD45β), and low androgen receptor expression. The cells demonstrate abundant cytoplasmic glycogen, evident by strong periodic acid–Schiff (PAS) reactivity. NEC8 maintains tumorigenicity in vitro while displaying typical embryonal carcinoma morphology with trophoblastic differentiation potential under specific conditions. NEC8 demonstrates high clonogenicity, rapid proliferation, and a less differentiated phenotype than other germ cell tumor derivatives, making it a useful model for studying aggressive testicular embryonal carcinoma biology and transformation.
| Product Code | NEC-8 |
| Species | Human |
| Cat.No | ABL-TC0464 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Testis |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Germ Cell Cancer Cell Lines |
NEC8 cell line plays a crucial role in testicular cancer research, particularly for studying pathogenesis and progression of embryonal carcinoma, a highly malignant subtype of non-seminomatous germ cell tumors. It is frequently used to investigate the molecular mechanisms underlying chemoresistance, aiding in identifying factors responsible for chemotherapeutic resistance in testicular germ cell tumors, offering insights into potential strategies to overcome this resistance. Moreover, NEC8 provides a platform the discovery and evaluation of novel immunotherapy targets, paving the way for the development of innovative, targeted treatment approaches to combat these aggressive malignancies.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
